Order Code PSYQP Psychotropic Pharmacogenomics Gene Panel, Varies
Additional Testing Requirements
Necessary Information
Prior Authorization is available, but not required, for this test. If proceeding with the prior authorization process, submit the required form with the specimen.
Specimen Required
Patient Preparation: A previous hematopoietic stem cell transplant from an allogenic donor will interfere with testing. For information about testing patients who have received a hematopoietic stem cell transplant, call 800-533-1710.
Submit only 1 of the following specimens:
Specimen Type: Whole blood
Container/Tube:
Preferred: Lavender top (EDTA)
Specimen Volume: 3 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
3. Whole blood collected postnatal from an umbilical cord is also acceptable. See Additional Information
Specimen Stability Information: Ambient 4 days (preferred)/Refrigerated 4 days/Frozen 4 days
Additional Information:
1. Specimens are preferred to be received within 4 days of collection. Extraction will be attempted for specimens received after 4 days, and DNA yield will be evaluated to determine if testing may proceed.
2. To ensure minimum volume and concentration of DNA are met, the requested volume must be submitted. Testing may be canceled if DNA requirements are inadequate.
3. For postnatal umbilical cord whole blood specimens, maternal cell contamination studies are recommended to ensure test results reflect that of the patient tested. A maternal blood specimen is required to complete maternal cell contamination studies. Order MATCC / Maternal Cell Contamination, Molecular Analysis, Varies on both the cord blood and maternal blood specimens under separate order numbers.
Specimen Type: Saliva
Patient Preparation: Patient should not eat, drink, smoke, or chew gum 30 minutes prior to collection.
Supplies:
DNA Saliva Kit High Yield (T1007)
Saliva Swab Collection Kit (T786)
Container/Tube:
Preferred: High-yield DNA saliva kit
Acceptable: Saliva swab
Specimen Volume: 1 Tube if using T1007 or 2 swabs if using T786
Collection Instructions: Collect and send specimen per kit instructions.
Specimen Stability Information: Ambient (preferred) 30 days/Refrigerated 30 days
Additional Information: Saliva specimens are acceptable but not recommended. Due to lower quantity/quality of DNA yielded from saliva, some aspects of the test may not perform as well as DNA extracted from a whole blood sample. When applicable, specific gene regions that were unable to be interrogated will be noted in the report. Alternatively, additional specimen may be required to complete testing.
Specimen Type: Extracted DNA
Container/Tube:
Preferred: Screw Cap Micro Tube, 2mL with skirted conical base
Acceptable: Matrix tube, 1 mL
Collection Instructions:
1. The preferred volume is at least 100 mcL at a concentration of 75 ng/mcL.
2. Include concentration and volume on tube.
Specimen Stability Information: Frozen (preferred) 1 year/Ambient/Refrigerated
Additional Information: DNA must be extracted in a CLIA-certified laboratory or equivalent and must be extracted from a specimen type listed as acceptable for this test (including applicable anticoagulants). Our laboratory has experience with Chemagic, Puregene, Autopure, MagnaPure, and EZ1 extraction platforms and cannot guarantee that all extraction methods are compatible with this test. If testing fails, one repeat will be attempted, and if unsuccessful, the test will be reported as failed and a charge will be applied. If applicable, specific gene regions that were unable to be interrogated due to DNA quality will be noted in the report.
Forms
1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available:
-Informed Consent for Genetic Testing (T576)
-Informed Consent for Genetic Testing-Spanish (T826)
2. Psychotropic Pharmacogenomics Gene Panel Prior Authorization Ordering Instructions
3. If not ordering electronically, complete, print, and send a Therapeutics Test Request (T831) with the specimen.
Useful For
Individualizing selection and dosage of medications prescribed for treatment of depression and other psychiatric disorders based on genetic variation
Identifying genetic variation in genes known to be associated with response and/or risk of toxicity with psychotropic medications
Evaluating patients who have failed therapy with selective serotonin reuptake inhibitors (SSRI)
Evaluating patients with treatment-resistant depression
Predicting response time to improvement with SSRI
Genetics Test Information
This test includes targeted testing to evaluate the following genes: ANKK1, ADRA2, CHRNA3, COMT, CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, DRD2, EPHX1, GRIK4, HLA-A*31:01, HLA-B*15:02, HTR2A, HTR2C, MTHFR, OPRM1, SCN1A, SLC6A4 (5-HTT), and UGT2B15.
CYP2D6 testing is done in 2 tiers when needed. Tier 1 uses a polymerase chain reaction (PCR)-based 5'-nuclease assay to determine the variants present. All samples also have copy number determined by PCR-based 5'-nuclease assay. Testing in tier 1 allows for the detection of all common CYP2D6 variants (eg, *2, *3, *4, *5, *6, *7, *8, *9, *10, *17, *29, *35, *41, *59) and rarer alleles such as *11, *12, *14, *15, and *114. Duplications and multiplications of alleles are also identified. Unitary and tandem CYP2D7-2D6 (*13) alleles and CYP2D6-2D7 (eg, *4N, *36, and *68) alleles can also be detected. Tier 2 testing involves sequencing using fluorescent dye-terminator chemistry and is only done if an ambiguous phenotype results from tier 1 testing. Approximately 3% of samples require tier 2 testing.
Prior Authorization is available for this assay.
Testing Algorithm
If a specimen requires follow-up for CYP2D6, then reflex testing will be performed as appropriate at an additional charge.
For cord blood specimens that have an accompanying maternal blood specimen, maternal cell contamination studies will be performed at an additional charge.
For more information see CYP2D6 Comprehensive Cascade Testing Algorithm.
Special Instructions
Method Name
Real-Time Polymerase Chain Reaction (RT-PCR) with Allelic Discrimination Analysis/Qualitative Allele-Specific RT-PCR/PCR followed by Sizing Analysis
Reporting Name
Psychotropic PGx Panel, VSpecimen Type
VariesSpecimen Minimum Volume
See Specimen Required
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Varies | Varies | |
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Reference Values
An interpretive report will be provided.
Method Description
Genomic DNA is extracted from the sample.
Genotyping for the following genes is performed using a polymerase chain reaction (PCR)-based 5'-nuclease assay. Fluorescently labeled detection probes anneal to the target DNA: ANKK1, ADRA2, CHRNA3, COMT, CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, DRD2, EPHX1, GRIK4, HTR2A, HTR2C, MTHFR, OPRM1, SCN1A, and UGT2B15. PCR is used to amplify the section of DNA that contains the variant. If the detection probe is an exact match to the target DNA, the 5'-nuclease polymerase degrades the probe, the reporter dye is released from the effects of the quencher dye, and a fluorescent signal is detected. Genotypes are assigned based on the allele-specific fluorescent signals that are detected.(Unpublished Mayo method)
Amplification for the HLA-B*15:02 and HLA-A*31:01 alleles and an internal control gene is performed by real-time PCR in the presence of SYBR Green, which fluoresces when bound to double-stranded DNA. A genotype is assigned based on the allele-specific SYBR Green fluorescent signals that are detected.(Unpublished Mayo method)
SLC6A4 is performed utilizing PCR amplification of the region surrounding the polymorphism followed by size separation of the products.(Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274[5292]:1527-1531)
CYP2D6 Copy Number Assay:
This assay utilizes a duplex real-time PCR, which includes 1 copy number probe and a reference assay per reaction. Each copy number probe detects the genomic sequence of interest and the reference assay detects a sequence that is known to be present in 2 copies in a diploid genome. Relative quantitation is used to determine the relative copy number of the target of interest in a genomic DNA (gDNA) sample normalized to10 ng/mcL for each probe. Each probe is normalized to the known copy number of the reference sequence, and compared to a calibrator sample with known copies of the target sequence included with each run.(Package insert: Taqman Copy Number Assays. Applied Biosystems; Revision D, 02/2019)
2D6 Sequencing Assays (Tier 2, as needed):
The CYP2D6 allele of interest is amplified by PCR. The PCR product is then purified and sequenced in both directions using fluorescent dye-terminator chemistry. Sequencing products are separated on an automated sequencer and trace files analyzed for variations in the exons and intron/exon boundaries of all 9 exons using mutation detection software and visual inspection.(Unpublished Mayo method)
Day(s) Performed
Varies
Performing Laboratory
Mayo Clinic Laboratories in Rochester
CPT Code Information
81418
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| PSYQP | Psychotropic PGx Panel, V | 94753-1 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 610209 | ADRA2A rs1800544 Genotype | 94401-7 |
| 610210 | ANKK1 rs1800497 Genotype | 94402-5 |
| 610211 | CHRNA3 rs1051730 Genotype | 94403-3 |
| 610212 | COMT rs4680 Genotype | 74511-7 |
| 610213 | CYP1A2 Genotype | 72884-0 |
| 610214 | CYP1A2 Phenotype | 94254-0 |
| 610215 | CYP2B6 Genotype | 72882-4 |
| 610216 | CYP2B6 Phenotype | 79720-9 |
| 610573 | CYP2B6 Activity Score | 104666-3 |
| 610217 | CYP2C19 Genotype | 57132-3 |
| 610218 | CYP2C19 Phenotype | 79714-2 |
| 610574 | CYP2C19 Activity Score | 104667-1 |
| 610219 | CYP2C9 Genotype | 46724-1 |
| 610220 | CYP2C9 Phenotype | 79716-7 |
| 610575 | CYP2C9 Activity Score | 104668-9 |
| 610221 | CYP2D6 Genotype | 40425-1 |
| 610222 | CYP2D6 Phenotype | 79715-9 |
| 610576 | CYP2D6 Activity Score | 104669-7 |
| 610223 | CYP3A4 Genotype | 81139-8 |
| 610224 | CYP3A4 Phenotype | 81145-5 |
| 610225 | CYP3A5 Genotype | 81140-6 |
| 610226 | CYP3A5 Phenotype | 79717-5 |
| 610227 | DRD2 rs1799978 Genotype | 94411-6 |
| 610228 | EPHX1 rs2234922 Genotype | 94412-4 |
| 610229 | GRIK4 rs1954787 Genotype | 94413-2 |
| 610230 | HLA-A*31:01 Genotype | 79712-6 |
| 610231 | HLA-B*15:02 Genotype | 57979-7 |
| 610232 | HTR2A rs7997012 Genotype | 93190-7 |
| 610233 | HTR2C rs3813929 Genotype | 93191-5 |
| 610234 | HTR2C rs1414334 Genotype | 93192-3 |
| 610235 | MTHFR Genotype | 94414-0 |
| 610236 | OPRM1 rs1799971 Genotype | 94415-7 |
| 610237 | SCN1A rs3812718 Genotype | 94416-5 |
| 610238 | SLC6A4 5HTTLPR Genotype | 94417-3 |
| 610239 | UGT2B15 rs1902023 Genotype | 94418-1 |
| 610240 | Interpretation | 69047-9 |
| 610241 | Additional Information | 48767-8 |
| 610242 | Method | 85069-3 |
| 610243 | Disclaimer | 62364-5 |
| 610244 | Reviewed by | 18771-6 |
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| 2D61Z | CYP2D6 Full Gene Sequence | No, (Bill Only) | No |
| 2D62Z | CYP2D6 GEN CYP2D6-2D7 Hybrid | No, (Bill Only) | No |
| 2D63Z | CYP2D6 GEN CYP2D7-2D6 Hybrid | No, (Bill Only) | No |
| 2D64Z | CYP2D6 Nonduplicated Gene | No, (Bill Only) | No |
| 2D65Z | CYP2D6 5' Gene DUP/MLT | No, (Bill Only) | No |
| 2D66Z | CYP2D6 3' Gene DUP/MLT | No, (Bill Only) | No |
| MATCC | Maternal Cell Contamination, B | No | No |
Prior Authorization
Insurance preauthorization is available for this testing; forms are available.
Patient financial assistance may be available to those who qualify. Patients who receive a bill from Mayo Clinic Laboratories will receive information on eligibility and how to apply.